Non-Clinical Topics   /   Pharmacy

Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies

USM By U.S. Medicine
April 5, 2013

WAYNE, NJ – Tthe U.S. Food and Drug Administration (FDA) has approved Bayer’s Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate, according to Bayer HealthCare and Onyx Pharmaceuticals, Inc. In September 2012, Stivarga was approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Stivarga is a Bayer compound developed by Bayer and jointly promoted by Bayer and Onyx in the United States.

 


Related Articles

How Veterans Feel About Remote Management of Their Care

While implantable devices have shown promise in reducing rehospitalization for heart failure (HF), VA researchers sought to determine if options that are less expensive and non-invasive would have comparable results.

Legislation: Clinicians Must Be Involved in Formulary Design, Purchasing

Legislation to prevent VA from outsourcing creation of its drug formulary and to require more input from medical professions is being considered in Congress.


U.S. Medicine Recommends


More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

Long-Acting Insulins Approved by FDA

VA’s Consolidated Mail Outpatient Pharmacy (CMOP) in Charleston, SC. New legislation is seeking to increase clinician input into formulary decisionmaking. WASHINGTON — Legislation to prevent VA from outsourcing creation of its drug formulary and to... View Article

FDA News

FDA Approves Option for Schizophrenia, Bipolar Treatment

VA’s Consolidated Mail Outpatient Pharmacy (CMOP) in Charleston, SC. New legislation is seeking to increase clinician input into formulary decisionmaking. WASHINGTON — Legislation to prevent VA from outsourcing creation of its drug formulary and to... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

VA’s Consolidated Mail Outpatient Pharmacy (CMOP) in Charleston, SC. New legislation is seeking to increase clinician input into formulary decisionmaking. WASHINGTON — Legislation to prevent VA from outsourcing creation of its drug formulary and to... View Article

FDA News

FDA Approves Tecfidera for Treatment of Relapsing MS

VA’s Consolidated Mail Outpatient Pharmacy (CMOP) in Charleston, SC. New legislation is seeking to increase clinician input into formulary decisionmaking. WASHINGTON — Legislation to prevent VA from outsourcing creation of its drug formulary and to... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up